Hydrogel Rectal Spacers in Prostate Cancer Treatment: Radiopaque vs. Non-radiopaque with Dr. Stock скачать в хорошем качестве

Hydrogel Rectal Spacers in Prostate Cancer Treatment: Radiopaque vs. Non-radiopaque with Dr. Stock

Richard D. Stock, MD, Director of Genito-Urinary Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, explores the role of rectal spacers in reducing gastrointestinal toxicity during prostate cancer radiotherapy. In this 21-minute presentation, Dr. Stock highlights the significant impact of radiation on rectal tissues, where standard treatment can lead to grade 2+ toxicities, including proctitis, rectal bleeding, and discomfort. Rectal spacers create a physical separation between the prostate and rectum, minimizing radiation exposure. Dr. Stock shares images demonstrating how hydrogel injections effectively push the prostate away from the rectum, reducing rectal dose and associated toxicities. Dr. Stock shares early research on hyaluronic acid and polyethylene glycol-based hydrogels, validating their ability to lower rectal radiation exposure and mitigate side effects. Advanced versions, such as SpaceOAR VueTM, incorporate contrast agents, enhancing visibility for precise placement and treatment planning. While spacer insertion requires skill, the proper technique ensures optimal separation and prevents complications. Clinical data suggest that rectal spacers should become an important component in prostate cancer radiotherapy, ensuring safer, more effective treatment.